全文获取类型
收费全文 | 234篇 |
免费 | 7篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 2篇 |
妇产科学 | 7篇 |
基础医学 | 22篇 |
临床医学 | 19篇 |
内科学 | 84篇 |
皮肤病学 | 3篇 |
神经病学 | 9篇 |
特种医学 | 17篇 |
外科学 | 58篇 |
综合类 | 2篇 |
药学 | 14篇 |
中国医学 | 2篇 |
肿瘤学 | 2篇 |
出版年
2023年 | 1篇 |
2022年 | 3篇 |
2021年 | 6篇 |
2019年 | 3篇 |
2018年 | 2篇 |
2017年 | 2篇 |
2015年 | 2篇 |
2014年 | 2篇 |
2013年 | 7篇 |
2012年 | 10篇 |
2011年 | 11篇 |
2010年 | 4篇 |
2009年 | 3篇 |
2008年 | 8篇 |
2007年 | 15篇 |
2006年 | 9篇 |
2005年 | 15篇 |
2004年 | 12篇 |
2003年 | 15篇 |
2002年 | 14篇 |
2001年 | 7篇 |
2000年 | 9篇 |
1999年 | 8篇 |
1998年 | 6篇 |
1997年 | 3篇 |
1996年 | 1篇 |
1995年 | 2篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1992年 | 2篇 |
1991年 | 7篇 |
1990年 | 8篇 |
1989年 | 10篇 |
1988年 | 10篇 |
1987年 | 3篇 |
1986年 | 4篇 |
1984年 | 1篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1973年 | 2篇 |
1966年 | 1篇 |
1963年 | 2篇 |
1961年 | 1篇 |
1936年 | 1篇 |
1892年 | 2篇 |
排序方式: 共有242条查询结果,搜索用时 15 毫秒
1.
Wladyslaw Mielczarski Antoni M. Zajaczkowski 《Optimal control applications & methods.》1994,15(1):49-65
The problem of multivariable controller synthesis for a turbogenerator is considered. Using the feedback linearization approach for multi-input non-linear systems, the existence of a linearizing state feedback for the improved reduced-order model of a turbogenerator is proved and the simplest form of this feedback is derived. Application of the obtained non-linear controller to the multivariable control of a turbogenerator provides very good results not only for the reduced-order model but also for the ‘exact’ (Park's) model of a turbogenerator. Simulations of fault and post-fault conditions in the obtained nonlinear control system confirm its superiority over a system with a voltage regulator and power system stabilizer. 相似文献
2.
Excess of DD homozygotes in haemodialysed patients with type II diabetes. The Diabetic Nephropathy Study Group 总被引:1,自引:0,他引:1
Schmidt S; Strojek K; Grzeszczak W; Bergis K; Ritz E 《Nephrology, dialysis, transplantation》1997,12(3):427-429
The role of the insertion/deletion polymorphism of the angiotensin-
converting enzyme (ACE) gene in the genesis of diabetic nephropathy has
been controversial. It has recently been proposed that progression occurs
more rapidly in individuals with diabetic and non-diabetic renal disease
who are homozygous for the D allele. We studied 658 patients with type II
diabetes, 347 without diabetic nephropathy and 311 with various stages of
diabetic nephropathy, and determined the I/D polymorphism of the ACE gene.
Patients at the extremes of renal risk, i.e. normotensive patients without
antihypertensive treatment and without nephropathy (n = 144), vs patients
on dialysis (n = 61), differed with respect to genotype (DD 36.8% vs 57.4%;
P = 0.007) and allele frequencies (D 0.59 vs 0.76; P < 0.001). In
contrast, patients with and without presumed nephropathy as assessed by
albuminuria did not differ with respect to DD genotype. In conclusion, in
this study, which was limited by sample size, patients with the highest
renal risk more frequently had the DD genotype. This would be compatible
with a greater risk of (or rate of) progression to end-stage renal failure.
相似文献
3.
Schmidt S.; Giessel R.; Bergis K. H.; Strojek K.; Grzeszczak W.; Ganten D.; Ritz E.; the Diabetic Nephropathy Study Group 《Nephrology, dialysis, transplantation》1996,11(9):1755-1761
BACKGROUND.: There is agreement that a family history of hypertension (HT),is a predictor for the risk of diabetic nephropathy (DN) inpatients with type 2 diabetes, and possibly also type 1 diabetes.It follows that genes related to the risk of hypertension mustalso be considered candidate genes for DN. The 235T allele ofthe angiotensinogen gene was found to be related to primaryHT. METHODS.: To examine whether it is predictive for DN as well, we examinedthe angiotensinogen gene polymorphism in 230 healthy local controls,423 patients with type 1 diabetes (n=180 with DN; n=243 withoutDN) and 663 patients with type 2 diabetes (n=310 with DN; n=353without DN). The angiotensinogen gene M235T polymorphism wasdetermined using PCR amplification. RESULTS.: The following results were obtained (i) no significant differenceof genotype distribution (type 1: MM/MT/TT(%) 27.6/57.2/15.2vs. 27.2/56.1/16.7 (P=0.92); type 2: MM/MT/TT (%) 31.7/48.2/20.1vs. 32.9/46.8/20.3 (P=0.93)) or allele frequencies (type 1:M 0.56 vs. 0.55 (P=0.795); type 2: M 0.56 vs. 0.56 (P=0.86))was found, between diabetic patients with or without DN, (ii)no difference was found between normotensive and hypertensivediabetic patients. CONCLUSION.: The data argue against a role of the angiotensinogen gene M235Tpolymorphism in the manifestation of diabetic nephropathy orhypertension in diabetic patients. 相似文献
4.
BACKGROUND: Chronic renal failure (CRF) is a complex phenotype that results from an underlying kidney disease and superimposing environmental and genetic factors. The aim of our study was to evaluate the role of polymorphisms in the genes encoding for components of the renin-angiotensin system (RAS) in the development and/or progression of CRF. METHODS: Two hundred forty-seven family trios (patients with CRF and both parents; 120 with primary chronic glomerulonephritis, 80 with interstitial nephritis, and 47 with type 1 diabetes with nephropathy) were examined, and transmission/disequilibrium test (TDT) was used to evaluate allele transmission from heterozygous parents to affected offspring. RESULTS: The D allele of the angiotensin I-converting enzyme (ACE) gene insertion/deletion polymorphism was transmitted significantly more frequently than expected for no association among all examined trios and in the subgroup of patients with interstitial nephritis. The angiotensinogen 235T allele was transmitted significantly more frequently to patients with CRF than expected for no association, but the effect was seen only in patients with interstitial nephritis. The presence of the DD or ID genotype was associated with a faster rate of decline of renal function, which was not observed for the angiotensinogen M235T polymorphism. For chymase gene and angiotensin II receptor type 1 gene, allele transmission did not deviate significantly from a random proportion of 50:50%. CONCLUSIONS: The results of this study suggest that ACE gene insertion/deletion and angiotensinogen M235T polymorphisms contribute to the increased risk for the development of CRF, but the magnitude of the effect within subsets of patients with specific etiologies of CRF must be evaluated further. 相似文献
5.
6.
Risk of macrovascular and microvascular complications in Type 2 diabetes: results of longitudinal study design 总被引:10,自引:0,他引:10
Nazimek-Siewniak B Moczulski D Grzeszczak W 《Journal of diabetes and its complications》2002,16(4):271-276
Type 2 diabetes is associated with the increased risk of microvascular and macrovascular complications. The aim of this study was to determine risk factors for the development of long-term complications of Type 2 diabetes. We analyzed medical records of all patients, who came with newly diagnosed Type 2 diabetes to one regional outpatient diabetes clinic from 1980 to 1994 (n=2175). The data, such as fasting plasma glucose, total cholesterol, triglyceride, blood pressure and body mass index (BMI), were assessed. Also, the time from the diagnosis of Type 2 diabetes to the occurrence of complications was obtained. Using the regression model in the survival analysis, we examined which of the risk factors determined the rate of the development of nephropathy, proliferative retinopathy, cardiovascular disease and stroke. Patients with higher fasting plasma glucose and higher mean blood pressure had higher risk of developing nephropathy and proliferative retinopathy. Higher mean arterial blood pressure was associated with higher rate of stroke and cardiovascular disease. High total cholesterol increased the hazard of coronary artery disease and proliferative retinopathy. In conclusion, blood pressure and fasting plasma glucose are major risk factors for microvascular complications in Type 2 diabetes. An increased blood pressure determined the macrovascular complications in Type 2 diabetes, but the effect of increased fasting plasma glucose could not be proved. 相似文献
7.
Alviar CL Tellez A Wang M Potts P Smith D Tsui M Budzynski W Raizner AE Kleiman NS Lev EI Granada JF Kaluza GL 《Journal of thrombosis and thrombolysis》2012,34(1):91-98
We previously found paclitaxel-eluting polymer-coated stents causing more human platelet-monocyte complex formation than bare metal stents in vitro. Presently, we examined patterns of platelet activation and adhesion after exposure to 6 nanofilm HAp-coated (HAp-nano) stents, 6 HAp-microporous-coated (HAp-micro) stents, 5 HAp sirolimus-eluting microporous-coated (HAp-SES) stents and 5 cobalt-chromium stents (BMS) deployed in an in vitro flow system. Blood obtained from healthy volunteers was circulated and sampled at 0, 10, 30 and 60 min. By flow cytometry, there were no significant differences in P-Selectin expression between the 4 stent types (HAp-nano = 32.5%; HAp-micro = 42.5%, HAp-SES = 10.23%, BMS = 7% change from baseline at 60 min, p = NS); PAC-1 antibody binding (HAp-nano = 11.8%; HAp-micro = 2.9%, HAp-SES = 18%, BMS = 6.4% change from baseline at 60 min, p = NS) or PMC formation (HAp-nano = 21.6%; HAp-micro = 4%, HAp-SES = 6.6%, BMS = 17.4% change from baseline at 60 min, p = NS). The 4 stent types did not differ in the average number of platelet clusters >10 μm in diameter by SEM (HAp-nano = 2.39 ± 5.75; HAp-micro = 2.26 ± 3.43; HAp-SES = 1.93 ± 3.24; BMS = 1.94 ± 2.41, p = NS). The majority of the struts in each stent group were only mildly covered by platelets, (HAp-nano = 80%, HAp-micro = 61%, HAp-SES = 78% and BMS = 52.1%, p = NS). The HAp-microporous-coated stents (ECD) attracted slightly more proteinaceous material than bare metal stents (HAp-micro = 35% struts with complete protein coverage, P < 0.0001 vs. other 3 stent types). In conclusion, biomimetic stent coating with nanofilm or microporous hydroxyapatite, even when eluting low-dose sirolimus, does not increase the platelet activation in circulating human blood, or platelet adhesion to stent surface when compared to bare metal stents in vitro. 相似文献
8.
Snit M Dwornicki M Zukowska-Szczechowska E Grzeszczak W 《Diabetes care》2007,30(1):189; author reply 189-189; author reply 190
9.
10.
Gilles Montalescot Stephen G. Ellis Mark A. de Belder Luc Janssens Olivier Katz Wladyslaw Pluta Patrick Ecollan Michal Tendera Ad J. van Boven Petr Widimsky Henning R. Andersen Amadeo Betriu Paul Armstrong Bruce R. Brodie Howard C. Herrmann Franz-Josef Neumann Mark B. Effron Jiandong Lu Elliot S. Barnathan Eric J. Topol 《JACC: Cardiovascular Interventions》2010,3(2):203-212